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To the Editor,
Systemic inflammation and generalized infection have 
been shown to be accompanied by significant cytokine-
mediated alterations in lipid and lipoprotein metabolism 
[1, 2]. Apolipoprotein M (ApoM) is a member of the lipoca-
lin protein family. Under normal conditions, most of the 
ApoM in plasma is associated with high-density lipopro-
tein (HDL). In humans, plasma ApoM concentration is 
approximately 0.9 μmol/L (23 mg/L) and correlates posi-
tively with plasma HDL, low-density lipoprotein (LDL), 
and total cholesterol [1, 3–5].
Previous studies indicated that ApoM concentrations 
are decreased in patients with sepsis, thus suggesting that 
ApoM may behave as a negative acute-phase reactant [1, 
3]. In the study herein described, ApoM levels were meas-
ured in postmortem serum from femoral blood in a series 
of sepsis-related fatalities and control cases that were sub-
jected to medicolegal investigations. Our aim was to deter-
mine whether ApoM could be determined in postmortem 
serum collected during autopsy. We furthermore wished 
to assess its diagnostic potential in identifying sepsis-
related deaths.
Two study groups were prospectively formed, a 
sepsis-related fatalities group and a control group. The 
sepsis-related fatalities group consisted of 20 cases. All 
individuals included in this group had been admitted to 
the intensive care unit of the local hospitals where they 
died. All cases had a documented, clinical diagnosis of 
sepsis in vivo (duration between 18 and 96 h). Sepsis was 
diagnosed on the basis of evidence of infection along 
with the presence of systemic inflammatory response 
syndrome, according to the definition of the American 
College of Chest Physicians/Society of Critical Care Medi-
cine [6].
Autopsies, histology, toxicology, biochemistry, and 
microbiology were performed in all cases. Postmortem 
intervals ranged between 6 and 62 h. ApoM measure-
ment was systematically carried out in postmortem serum 
obtained from femoral blood. Sepsis and multiple organ 
dysfunction syndrome as causes of death were confirmed 
by postmortem investigations in all cases. Alternative 
causes of death were excluded on the basis of postmortem 
investigation results. According to medical records as well 
as antemortem and postmortem biochemical results, none 
of these subjects had diabetes mellitus or lipid disorders. 
The descriptive characteristics of the studied subjects are 
reported in Table 1.
The control group consisted of 20 age-, race-, and 
sex-matched forensic autopsy cases. None of the subjects 
included in this group had a documented, clinical diag-
nosis of sepsis in vivo and none had been admitted to the 
hospital before death. Autopsies, histology, toxicology, 
biochemistry, and microbiology were performed between 
8 and 64 h after death. Postmortem investigations failed 
to reveal findings consistent with the existence of underly-
ing bacterial infections. According to medical records and 
postmortem biochemical results, none of these subjects 
had diabetes mellitus or lipid disorders. Complications of 
diabetes mellitus as causes of death were also excluded. 
The descriptive characteristics of the studied subjects are 
reported in Table 1.
Personal data pertaining to both studied groups were 
collected from clinical patient databases and medical 
records obtained from general practitioners and local 
health services. In all sepsis cases, antemortem clini-
cal data were only collected after having performed 
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postmortem investigations. Procalcitonin (PCT) and 
C-reactive protein (CRP) were measured in all sepsis cases 
during hospitalization.
As all cases selected for the control group originated 
from forensic practice with deaths occurring outside the 
hospital in all cases, laboratory analysis results shortly 
before death were unavailable. PCT, CRP, lipopolysac-
charide-binding protein (LBP), ApoM, HDL-cholesterol, 
LDL-cholesterol, and total cholesterol were systematically 
measured in postmortem serum from femoral blood.
Peripheral blood was collected by aspiration through 
the femoral vein(s) during autopsy. Blood was centri-
fuged immediately after collection at 3000 g for 15 min. 
After centrifugation, the separated supernatant (postmor-
tem serum) was collected and stored in preservative-free 
tubes. PCT, CRP, and LBP concentrations were deter-
mined according to the techniques previously described 
[7, 8]. The stability of PCT, CRP, and LBP in postmortem 
serum was assumed on the basis of information from 
currently available forensic literature [7, 8]. ApoM was 
measured in postmortem serum with a commercialized 
specific enzyme-linked immunosorbent assay (ELISA) kit, 
according to the manufacturer protocol (Human Apolipo-
protein M, APOM ELISA kit; CUSABIO, Wuhan, China). 
Results were expressed in μmol/L and mg/L. ApoM cutoff 
values in postmortem serum were not preliminarily iden-
tified owing to the unavailability of previous studies on 
postmortem material for comparison. HDL-cholesterol, 
LDL-cholesterol, and total cholesterol were measured in 
postmortem serum from femoral blood using an enzy-
matic colorimetric method (CHOD-PAP method). Results 
were expressed in mmol/L and mg/dL.
Non-parametric tests were used throughout the study. 
The Mann-Whitney U-test was used to evaluate the differ-
ences between sepsis and control cases. A p-value of  < 0.05 
was considered significant for all tests. Graphpad Prism 
4.0 (Graphpad Software, La Jolla, CA, USA) was used for 
statistics.
Table 2 summarizes the ranges, mean values, medians, 
and standard deviations (SDs) for all tested parameters 
in both studied groups. As expected, postmortem serum 
PCT, CRP, and LBP values were significantly higher in the 
sepsis group (p < 0.0001) and were consistent with the pres-
ence of generalized inflammation and bacterial infection. 
Total cholesterol, LDL-cholesterol, and HDL-cholesterol 
behaved comparably in both studied groups, with signifi-
cantly lower levels in septic cases (p < 0.05). ApoM values 
in the septic group were significantly lower (p < 0.0001). 
No correlation between ApoM values and postmortem 
intervals was observed in either sepsis or control cases. 
Lastly, postmortem serum PCT and CRP concentrations 
were systematically lower than the corresponding ante-
mortem values, as expected on the basis of the available 
forensic literature.
Table 1 Descriptive characteristics of the studied subjects.
Sepsis 
cases


















1   Male 48   75   178   23.7   1  Male 49   74   177   23.9
2   Male 54   80   181   24.4   2  Male 55   81   182   24.5
3   Male 39   74   176   23.9   3  Male 40   75   178   23.7
4   Female 62   62   168   22.0   4  Female 62   60   169   21.0
5   Female 68   59   166   21.4   5  Female 67   60   170   20.8
6   Male 49   77   177   24.6   6  Male 48   76   175   24.8
7   Male 50   78   180   24.1   7  Male 51   75   179   23.4
8   Female 51   52   159   20.6   8  Female 50   51   158   20.4
9   Male 50   80   185   23.4   9  Male 49   81   187   23.2
10   Male 67   81   182   24.5   10  Male 66   78   178   24.6
11   Male 69   75   175   24.5   11  Male 69   74   176   23.9
12   Female 44   59   160   23.0   12  Female 45   56   159   22.2
13   Female 65   54   158   21.6   13  Female 64   55   156   22.6
14   Male 60   73   174   24.1   14  Male 61   74   178   23.4
15   Male 59   79   182   23.8   15  Male 60   77   177   24.6
16   Female 71   59   170   20.4   16  Female 72   60   172   20.3
17   Male 70   84   184   24.8   17  Male 71   78   185   22.8
18   Male 49   78   179   24.3   18  Male 48   74   175   24.2
19   Male 46   81   183   24.2   19  Male 46   77   181   23.5
20   Female 51   56   161   21.6   20  Female 51   57   162   21.7
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  HDL, mmol/L 
(mg/dL)
  LDL, mmol/L 
(mg/dL)
  Total cholesterol, 
mmol/L (mg/dL)
  ApoM, μmol/L 
(mg/dL)
Septic group (n = 20)
 Ranges   1.99–6.16   65–235   11–50   0.39–1.17 (15–45)   1.42–2.46 (55–95)   2.46–3.39 (95–131)   0.23–0.74 (6–19)
 Mean   3.20   94.50   20.50   0.79 (30.50)   1.97 (76.00)   2.83 (109.50)   0.47 (12.00)
 Median   3.37   108.00   24.10   0.78 (30.00)   1.95 (75.25)   2.85 (110.20)   0.47 (12.10)
 SD   1.12   40.27   10.60   0.20 (7.71)   0.24 (9.11)   0.24 (9.27)   0.12 (3.13)
Controls (n = 20)
 Ranges   0.06–0.19   3–12   3–12   0.47–3.11 (18–120)   2.59–3.89 (100–150)   4.09–5.70 (158–220)   0.78–1.25 (20–32)
 Mean   0.07   8.50   5.00   1.20 (46.50)   3.25 (125.50)   4.92 (190.00)   1.04 (26.50)
 Median   0.08   7.85   5.05   1.32 (50.95)   3.25 (125.60)   4.89 (188.80)   1.04 (26.45)
 SD   0.04   2.13   2.06   0.67 (25.75)   0.33 (12.57)   0.54 (20.84)   0.14 (3.56)
Abbreviations are reported in the text.
Cytokines produced during systemic inflammation are 
known to mediate significant modifications in lipid and 
lipoprotein metabolism. Triglyceride and very low density 
lipoprotein (VLDL) increases are commonly observed during 
inflammation and are the consequences of both decreased 
triglyceride clearance and enhanced VLDL production. Fur-
thermore, total cholesterol, LDL, and HDL decreases are also 
commonly found. Inflammatory HDL particles are increased 
in size and modified in lipid profile, metabolism, and func-
tion. As a result of these changes, HDL loses its antioxidant 
and anti-inflammatory properties [1, 3, 9].
ApoM was speculated as contributing to the anti-
inflammatory properties of HDL as soon as it was identi-
fied as one of its components [3–5, 9]. Indeed, inhibition of 
ApoM production was demonstrated to result in decreased 
HDL levels, increased HDL size, and impaired transport of 
cholesterol out of macrophages to HDL. Conversely, ApoM 
overexpression was demonstrated to limit atherosclerotic 
lesion size [1, 3, 5, 9]. The results of our analyses seem to 
indicate that, as in the clinical field, decreased ApoM con-
centrations can be measured in septic cases investigated 
after death. Analogously, decreases in total cholesterol, 
HDL-cholesterol, and LDL-cholesterol that may character-
ize severe sepsis and septic shock in the living can also be 
identified in postmortem samples.
Although our research has yielded some interesting 
findings, the limitations of our study must be acknowl-
edged. The first is the relatively small number of sub-
jects, which may limit research accuracy. A further limit 
concerns the present unavailability of detailed studies on 
ApoM behavior in the postmortem setting, rendering our 
observations mostly speculative.
To conclude, the study herein presented is the 
first attempt at measuring ApoM values in postmortem 
serum in septic and control cases that were subjected to 
medicolegal investigations. Within the aforementioned 
limits, the results of our investigations indicate that ApoM 
can be measured in postmortem samples and may be a 
useful biomarker in identifying sepsis-related deaths.
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